Department of Orthopaedic Surgery, Nicklaus Children's Hospital, Center for Spine Disorders and Scoliosis Surgery, Miami, FL.
Department of Orthopedic Surgery, The University of Connecticut, Farmington, CT.
Clin Spine Surg. 2024 Apr 1;37(3):E158-E161. doi: 10.1097/BSD.0000000000001569. Epub 2024 Jan 5.
Retrospective cohort study.
The goal of this study is to evaluate the effects of preoperative lumbar epidural steroid injection on the rate of pseudarthrosis following lumbar spine fusion surgery.
Epidural corticosteroids help to reduce nerve root edema and suppress proinflammatory cytokines in patients with radiculopathy. Corticosteroids may inhibit bone formation and reduce bone matrix synthesis rates. Thus, there is concern that corticosteroids may reduce lumbar fusion capability, potentially resulting in increased rates of symptomatic pseudarthrosis.
We identified all patients who underwent 1-level or 2-level lumbar fusion surgery between 2018 and 2022. Patients were categorized into one of 3 groups: no preoperative epidural steroid injection (ESI) history (group 0), preoperative ESI within 90 days of surgery (group 1), or most recent ESI >90 days before surgery (group 2). The primary outcome of this study was pseudarthrosis. Binominal regression analyses were performed to determine the relationships between potential risk factors (sex, age, body mass index, smoking history, diabetes status, history of systemic steroid use, preoperative ESI, perioperative intravenous steroid administration, type of surgery, and postoperative ESI within 6 mo) and the development of postoperative pseudarthrosis.
A total of 446 patients were included in this study. Of those, 106 patients (23.7%) did not have a preoperative ESI (group 0), 132 patients (29.5%) had an ESI within 90 days of surgery (group 1), and 208 patients (46.6%) had their most recent ESI >90 days before surgery (group 2). The overall incidence of pseudarthrosis following lumbar fusion was 8.7% (39 of 446). Although the incidence of pseudarthrosis following ESI at any time point was higher than in our control cohort (group 0), this difference was not statistically significant.
This study found no increased risk of postoperative pseudarthrosis in patients who underwent 1-level or 2-level lumbar fusions after preoperative ESI.
Level III.
回顾性队列研究。
本研究旨在评估腰椎硬膜外类固醇注射术前对腰椎融合术后假关节形成率的影响。
硬膜外皮质类固醇有助于减轻神经根水肿并抑制根性病变患者的促炎细胞因子。皮质类固醇可能抑制骨形成并降低骨基质合成率。因此,人们担心皮质类固醇可能会降低腰椎融合能力,从而导致症状性假关节形成率增加。
我们确定了 2018 年至 2022 年间接受 1 或 2 个节段腰椎融合术的所有患者。患者分为 3 组之一:无术前硬膜外类固醇注射(ESI)史(组 0)、术前 ESI 距手术 90 天内(组 1)或最近一次 ESI 距手术 90 天以上(组 2)。本研究的主要结局为假关节形成。进行二项回归分析以确定潜在危险因素(性别、年龄、体重指数、吸烟史、糖尿病状态、系统性类固醇使用史、术前 ESI、围手术期静脉内类固醇给药、手术类型和术后 6 个月内 ESI)与术后假关节形成之间的关系。
本研究共纳入 446 例患者。其中,106 例(23.7%)患者无术前 ESI(组 0),132 例(29.5%)患者 ESI 距手术 90 天内(组 1),208 例(46.6%)患者最近一次 ESI 距手术 90 天以上(组 2)。腰椎融合术后假关节形成的总发生率为 8.7%(39/446)。尽管任何时间点 ESI 后假关节形成的发生率均高于我们的对照组(组 0),但差异无统计学意义。
本研究发现腰椎融合术前接受 ESI 的患者术后发生假关节的风险并未增加。
III 级。